Clicky

Santhera Pharmaceuticals Holding AG(SANN)

Description: Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.


Keywords: Medicine Pharmaceutical Organ Systems Dystrophy Muscular Dystrophy Cystic Fibrosis Duchenne Muscular Dystrophy Antioxidants Leber's Hereditary Optic Neuropathy

Home Page: www.santhera.com

Hohenrainstrasse 24
Pratteln, 4133
Switzerland
Phone: 41 61 906 89 50


Officers

Name Title
Dr. Thomas Meier Ph.D. Founder & Chairman
Mr. Dario Eklund Chief Exec. Officer
Mr. Andrew P. Smith CGMA, FCMA Chief Financial Officer
Mr. Marc Schrader Head of Technical Devel. & Operations
Ms. Eva Kalias Head of Investor Relations & Communications
Mr. Oliver Strub Exec. VP, Gen. Counsel & Sec.
Mr. Neville Kodkani M.D. Head of Global Marketing & Partner Management
Ms. Sarah Holmes-Klotz Head of People & Culture
Mr. Günther Metz Ph.D. Head of Bus. Devel. & Exec. VP
Mr. Shabir Hasham M.D. Chief Medical Officer

Exchange: SW

Country: CH : Switzerland

Currency: Swiss Franc (CHF)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 30.5244
Price-to-Sales TTM: 276.1904
IPO Date:
Fiscal Year End: December
Full Time Employees: 39
Back to stocks